Plain-English translation of NCT06990542 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new approach to radiation therapy for prostate cancer that uses advanced imaging to precisely locate tumors and deliver high doses of radiation directly to them, while giving lower doses to the rest of the prostate. The goal is to keep the cancer-fighting benefits of standard radiation therapy while reducing long-term side effects to your bladder, rectum, and other nearby organs.
Currently, standard radiation therapy for prostate cancer treats the entire prostate gland with the same dose. This can cause long-term side effects like bowel and urinary problems that affect quality of life. Researchers believe that if they can identify exactly where the tumor is using advanced imaging and focus the radiation dose there, they can reduce damage to healthy tissue while still effectively treating the cancer.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either standard radiation therapy or the new image-guided tumor-focused radiation therapy. Both groups will undergo similar imaging and treatment planning, with the key difference being how the radiation dose is distributed. You will come in for regular radiation treatments and follow-up visits to monitor your side effects and cancer outcomes over time.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States